Aespira Ltd. is setting a new standard for single-use disposable dry-powder inhalers (DPIs).  The company’s inhalers will deliver high-performance at low cost, and provide a relative advantage to pharma companies in delivering a range of drugs.

The company’s inhalers are especially appropriate for delivery of drugs requiring any or all of the following key features:

• Prevention of contamination and cross-contamination

• Simple use by non-trained patients

• Single-dose and/or non-chronic usage

• Clear audible dose confirmation

• Delivery of combination therapies where the drugs powders are stored separately but delivered together